# Empirical Intravenous Beta-Lactam Plus Metronidazole Vs Oral Cefixime Plus Metronidazole for the Treatment of Liver Abscess

> **NCT06847126** · PHASE3 · RECRUITING · sponsor: **Post Graduate Institute of Medical Education and Research, Chandigarh** · enrollment: 220 (estimated)

## Conditions studied

- Liver Abscess

## Interventions

- **DRUG:** Intravenous beta-lactam antimicrobial for 2 weeks Plus Intravenous Metronidazole (750 mg q 8 hourly) for 2 weeks
- **DRUG:** Tablet Cefixime (200 mg q 12 hourly) for 2 weeks Plus Tablet Metronidazole (800 mg q 8 hourly) for 2 weeks
- **OTHER:** Standard medical care

## Key facts

- **NCT ID:** NCT06847126
- **Lead sponsor:** Post Graduate Institute of Medical Education and Research, Chandigarh
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-25
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2025-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06847126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06847126, "Empirical Intravenous Beta-Lactam Plus Metronidazole Vs Oral Cefixime Plus Metronidazole for the Treatment of Liver Abscess". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06847126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*